Lonza Group Ltd (LZAGY)
62.99
+1.32
(+2.14%)
USD |
OTCM |
Nov 01, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 45.43B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 80.19% |
| Valuation | |
| PE Ratio | 71.05 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 6.089 |
| Price to Book Value | 4.367 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.4405 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.4058 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 59.14% |
Profile
| Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations. |
| URL | https://www.lonza.com |
| Investor Relations URL | https://www.lonza.com/investor-relations |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Jan. 24, 2025 (est.) |
| Last Earnings Release | Jul. 25, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 15, 2024 |
Ratings
Profile
| Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations. |
| URL | https://www.lonza.com |
| Investor Relations URL | https://www.lonza.com/investor-relations |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Jan. 24, 2025 (est.) |
| Last Earnings Release | Jul. 25, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 15, 2024 |